Pay in 4 interest-free payments of $5.74 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
2016-2017 Researchers start clinical trials that evaluate semaglutide efficacy in blood sugar control and cardiovascular risk reduction are conducted
Similarly, its not meant for large-volume IV infusion
Cardiovascular Outcomes Liraglutide (LEADER trial): 13% reduction in major adverse cardiovascular events (MACE) in patients with Type 2 diabetes and high cardiovascular risk Statistically significant cardiovascular protection Semaglutide (SELECT trial): 20% reduction in MACE in patients with obesity and established cardiovascular disease Studied specifically for cardiovascular outcomes in obesity (not just diabetes) Both medications provide cardiovascular protection, but semaglutides evidence is more recent, more robust, and specifically applicable to patients with obesity regardless of diabetes status
There should be a generic form of liraglutide released in the UK later this year.
US$ 22.12
US$ 23.64
US$ 22.78
US$ 24.85
US$ 28.71
US$ 22.36
